The Future Looks Bright for Oscar Health Stock

Oscar Health (OSCR) exhibits strong technical momentum, recently setting a new all-time high.

The stock is up more than 55% over the past year.

OSCR's fundamentals are robust. Revenue is projected to grow 60.17% this year, with earnings estimated to rise 203.58%.

Analyst sentiment is broadly positive, with multiple "Strong Buy" ratings and price targets ranging from $25 to $39.

Valued at $10.2 billion, Oscar Health (OSCR) is a digital health insurance company.

I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. OSCR checks those boxes. The Trend Seeker issued a new "Buy" signal on Sept. 3. Since then, the stock has lost 2.88%.

Barchart's Technical Indicators for Oscar Health

Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

Oscar Health scored a 5-year high of $33.55 on August 24.

Oscar Health has a Weighted Alpha of 76.44.

OSCR has a 96% "Buy" opinion from Barchart.

The stock has gained 55.91% over the past 52 weeks.

Oscar Health has its Trend Seeker "Buy" signal intact.

The stock recently traded at $31.33 with a 50-day moving average of $30.51.

OSCR had 6 new highs and gained12.04% in the last month.

Relative Strength Index (RSI) is at 52.43.

There's a technical support level around $31.90.

Revenue is projected to grow 60.17% this year and another 8.28% next year.

Earnings are estimated to increase by 203.58% this year and an additional 7.50% next year.

Analyst and Investor Sentiment on Oscar Health

The Wall Street analysts followed by Barchart give the stock 3 "Strong Buy," 1 "Moderate Buy," 7 "Hold," and 1 "Moderate Sell" opinion with price targets between $25 and $39.

Morningstar thinks the stock is 12% overvalued.

CFRA's MarketScope rates the stock as "Strong Buy."

17,560 investors are following the stock on Seeking Alpha, which rates it a "Strong Buy" and rates it the best Life & Health Insurance stock.

TipRanks' analysts' price target is $30.57.

Short interest is 5.33% of the float with 2.34 days to cover the float.